LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration ...
-Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 monthsAn analysis of ...
- LEO Pharma announces a co-creation agreement with the National Psoriasis Foundation ...
- Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development ...
- LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into ...
- * LEO Pharma has conducted the first truly large scale international study informed by both ...
- LEO Pharma is now actively searching for new global or territorial ...
- - NOT INTENDED FOR US MEDIA - Ingenol Mebutate is an ...